Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Advanced Non-Clear Cell Renal Cell Carcinoma

NCT04413123 is registered in ClinicalTrials.gov with Bradley A. McGregor, MD as lead sponsor.

NCT NCT04413123
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04413123 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Advanced Non-Clear Cell Renal Cell Carcinoma
Lead sponsor
Bradley A. McGregor, MD
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 5, 2020
Completion date
June 20, 2027
Enrollment
60 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

chromophobe renal cell carcinoma, collecting duct renal cell carcinoma, metastatic ncc renal cell carcinoma, papillary renal cell carcinoma, renal cell carcinoma, translocation renal cell carcinoma, unclassified renal cell carcinoma, unresectable advanced renal cell carcinoma